Cargando…
Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer
Previous studies on monocarboxylate transporters expression in prostate cancer (PCa) have shown that monocarboxylate transporter 2 (MCT2) was clearly overexpressed in prostate malignant glands, pointing it out as a putative biomarker for PCa. However, its localization and possible role in PCa cells...
Autores principales: | Valença, Isabel, Pértega-Gomes, Nelma, Vizcaino, José Rámon, Henrique, Rui M, Lopes, Carlos, Baltazar, Fátima, Ribeiro, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395187/ https://www.ncbi.nlm.nih.gov/pubmed/25639644 http://dx.doi.org/10.1111/jcmm.12481 |
Ejemplares similares
-
Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
por: Pértega-Gomes, Nelma, et al.
Publicado: (2011) -
Prostate Cancer Proliferation Is Affected by the Subcellular Localization of MCT2 and Accompanied by Significant Peroxisomal Alterations
por: Valença, Isabel, et al.
Publicado: (2020) -
Clinical impact of the metabolic phenotype of prostate cancer: role of monocarboxylate transporters (MCTs)
por: Pértega-Gomes, Nelma, et al.
Publicado: (2013) -
Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
por: Pértega-Gomes, Nelma, et al.
Publicado: (2014) -
A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer
por: Pértega-Gomes, Nelma, et al.
Publicado: (2014)